Table 5.
Clinical Characteristics | N = 22 individuals |
---|---|
Disease history | Total number N (%) or mean (± SD) |
Type 2 diabetes mellitus | 22 (100) |
Time since diabetes diagnosis [yrs] | 6.4 (± 5.0) |
Hyperlipidemia | 19 (86) |
Hypertension | 19 (86) |
Past myocardial infarction | 0 (0) |
Coronary artery disease | 4 (18) |
Peripheral vascular disease | 3 (14) |
Cerebrovascular disease | 1 (5) |
Diabetic retinopathy | 1 (5) |
Diabetic nephropathya | 8 (36) |
Blood marker levels | Total number N (%) |
Glycosylated hemoglobin A1c (HbA1c) ≥ 7%b | 9 (41)c |
Myeloperoxidase (MPO) ≥ 7 ng/mlb | 41 (51)d |
Ferritin ≥ 60 ng/mlb | 36 (41)e |
Adiponectin < 3700 ng/mlb | 11 (50)f |
Homocysteine ≥ 12 μmol/lb | 11 (50)c |
Medication intake | Total number N (%) |
Sulfonylureas | 10 (45) |
Thiazolidinediones | 6 (27) |
Metformin | 14 (64) |
Statins | 12 (55) |
Aspirin | 14 (64) |
Beta-adrenergic receptor blockers (BB) | 9 (41) |
Angiotensin converting enzyme-inhibitors | 12 (55) |
Calcium-blockers | 2 (9) |
Diuretics | 8 (36) |
Angiotension II-receptor blocker | 3 (14) |
Estrogen | 2 (9) |
aBased on the screening urine (>30 μg albumin/mg creatinine) on spot collection
bGlycosylated hemoglobin A1c was only measured once, myeloperoxidase, adiponectin and homocysteine were measured on all four visits. For the interaction analysis with myeloperoxidase all observations per patient were used as it showed high daily variation within individuals. For ferritin all observations per patient were used as there were some single missing observations - however, there was only low daily variation within individuals. For the interaction analysis with adiponectin the mean of the four measurements per individual was used. For homocyteine the mean of the four measurements per individual was calculated.
cData was missing from two subjects.
dData was missing for 8 observations.
eData was missing for 14 observations.
fData was missing from one subject.